MDL 100,907: A Selective 5‐HT2A Receptor Antagonist for the Treatment of Schizophrenia
Open Access
- 1 March 1997
- journal article
- Published by Wiley in CNS Drug Reviews
- Vol. 3 (1), 49-67
- https://doi.org/10.1111/j.1527-3458.1997.tb00316.x
Abstract
No abstract availableKeywords
This publication has 76 references indexed in Scilit:
- Effects of Olanzapine on Regional C-Fos Expression in Rat ForebrainNeuropsychopharmacology, 1996
- Stimulant-induced disruption of non-human primate social behavior and the psychopharmacology of schizophreniaJournal of Psychopharmacology, 1996
- The selective 5-HT2a receptor antagonist MDL 100,907 counteracts the psychomotor stimulation ensuing manipulations with monoaminergic, glutamatergic or muscarinic neurotransmission in the mouse ? implications for psychosisJournal of Neural Transmission, 1995
- The role of 5-HT2A receptors in antipsychotic activityLife Sciences, 1995
- Evidence for biochemical heterogeneity in schizophrenia: a multivariate study of monoaminergic indices in human post-mortal brain tissueJournal of Neural Transmission, 1994
- Contribution of serotonin neurotoxins to understanding psychiatric disordersInternational Clinical Psychopharmacology, 1993
- Effects of dizocilpine (MK-801) on rat midbrain dopamine cell activity: differential actions on firing pattern related to anatomical localizationJournal of Neural Transmission, 1993
- Interactions between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson's diseaseTrends in Neurosciences, 1990
- Ketanserin pretreatment attenuates MDMA-induced dopamine release in the striatum as measured by microdialysisLife Sciences, 1990
- The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted miceJournal of Neural Transmission, 1989